Related content

Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933

By van Zuylen L.   Sparreboom A.   van der Gaast A.   Nooter K.   Eskens F.A.L.M.   Brouwer E.   Bol C.J.   de Vries R.   Palmer P.A.   Verweij J.  

European Journal of Cancer, Vol. 38, Iss. 8, 2002-05 ,pp. : 1090-1099

Elsevier

Access to resources Recommend Favorite

Phase II Trial Assessing Granulocyte-macrophage—Colony Stimulating Factor, Ketoconazole Plus Mitoxantrone in Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel Treatments

By Amato Robert J.   Saxena Somyata   Stepankiw Mika  

Cancer Investigation, Vol. 31, Iss. 3, 2013-03 ,pp. : 177-182

Informa Healthcare

Access to resources Recommend Favorite

Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/ neu in Patients with Breast Cancer

By Taucher Susanne  

Breast Cancer Research and Treatment, Vol. 82, Iss. 3, 2003-01 ,pp. : 207-213

Springer Publishing Company

Access to resources Recommend Favorite

Docetaxel extravasation

By Berghammer P.   Pöhnl R.   Baur M.   Dittrich C.  

Supportive Care in Cancer, Vol. 9, Iss. 2, 2001-03 ,pp. : 131-134

Springer Publishing Company

Access to resources Recommend Favorite

Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial - an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group Study

By Pectasides D.   Visvikis A.   Aspropotamitis A.   Halikia A.   Karvounis N.   Dimitriadis M.   Athanassiou A.  

European Journal of Cancer, Vol. 36, Iss. 1, 2000-01 ,pp. : 74-79

Elsevier

Access to resources Recommend Favorite